26556230|t|Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models.
26556230|a|INTRODUCTION: Amyloid beta (Abeta) accumulates in the extracellular space as diffuse and neuritic plaques in Alzheimer's disease (AD). Abeta also deposits on the walls of arterioles as cerebral amyloid angiopathy (CAA) in most cases of AD and sometimes independently of AD. Apolipoprotein E (apoE) e4 is associated with increases in both Abeta plaques and CAA in humans. Studies in mouse models that develop Abeta deposition have shown that murine apoE and human apoE4 have different abilities to facilitate plaque or CAA formation when studied independently. To better understand and compare the effects of murine apoE and human apoE4, we bred 5XFAD (line 7031) transgenic mice so that they expressed one copy of murine apoE and one copy of human apoE4 under the control of the normal murine apoE regulatory elements (5XFAD/apoE(m/4)). RESULTS: The 5XFAD/apoE(m/4) mice contained levels of parenchymal CAA that were intermediate between 5XFAD/apoE(m/m) and 5XFAD/apoE(4/4) mice. In 5XFAD/apoE(m/4) mice, we found that Abeta parenchymal plaques co-localized with much more apoE than did parenchymal CAA, suggesting differential co-aggregation of apoE with Abeta in plaques versus CAA. More importantly, within the brain parenchyma of the 5XFAD/apoE(m/4) mice, plaques contained more murine apoE, which on its own results in more pronounced and earlier plaque formation, while CAA contained more human apoE4 which on its own results in more pronounced CAA formation. We further confirmed the co-aggregation of mouse apoE with Abeta in plaques by showing a strong correlation between insoluble mouse apoE and insoluble Abeta in PS1APP-21/apoE(m/4) mice which develop plaques without CAA. CONCLUSIONS: These studies suggest that both murine apoE and human apoE4 facilitate differential opposing effects in influencing Abeta plaques versus CAA via different co-aggregation with these two amyloid lesions and set the stage for understanding these effects at a molecular level.
26556230	0	6	Murine	Species	10090
26556230	14	19	human	Species	9606
26556230	20	37	apolipoprotein E4	Gene	348
26556230	91	118	cerebral amyloid angiopathy	Disease	MESH:D016657
26556230	123	138	amyloid plaques	Disease	MESH:D058225
26556230	157	162	mouse	Species	10090
26556230	185	197	Amyloid beta	Gene	351
26556230	199	204	Abeta	Gene	351
26556230	269	276	plaques	Disease	MESH:D003773
26556230	280	299	Alzheimer's disease	Disease	MESH:D000544
26556230	301	303	AD	Disease	MESH:D000544
26556230	306	311	Abeta	Gene	351
26556230	356	383	cerebral amyloid angiopathy	Disease	MESH:D016657
26556230	385	388	CAA	Disease	MESH:D016657
26556230	407	409	AD	Disease	MESH:D000544
26556230	441	443	AD	Disease	MESH:D000544
26556230	445	461	Apolipoprotein E	Gene	348
26556230	463	467	apoE	Gene	348
26556230	509	514	Abeta	Gene	351
26556230	515	522	plaques	Disease	MESH:D003773
26556230	527	530	CAA	Disease	MESH:D016657
26556230	534	540	humans	Species	9606
26556230	553	558	mouse	Species	10090
26556230	579	584	Abeta	Gene	11820
26556230	612	618	murine	Species	10090
26556230	619	623	apoE	Gene	348
26556230	628	633	human	Species	9606
26556230	634	639	apoE4	Gene	348
26556230	689	692	CAA	Disease	MESH:D016657
26556230	779	785	murine	Species	10090
26556230	786	790	apoE	Gene	348
26556230	795	800	human	Species	9606
26556230	801	806	apoE4	Gene	348
26556230	816	821	5XFAD	CellLine	CVCL:5U93
26556230	845	849	mice	Species	10090
26556230	885	891	murine	Species	10090
26556230	892	896	apoE	Gene	348
26556230	913	918	human	Species	9606
26556230	919	924	apoE4	Gene	348
26556230	957	963	murine	Species	10090
26556230	964	968	apoE	Gene	348
26556230	990	995	5XFAD	CellLine	CVCL:5U93
26556230	996	1000	apoE	Gene	348
26556230	1021	1026	5XFAD	CellLine	CVCL:5U93
26556230	1027	1031	apoE	Gene	348
26556230	1037	1041	mice	Species	10090
26556230	1074	1077	CAA	Disease	MESH:D016657
26556230	1109	1114	5XFAD	CellLine	CVCL:5U93
26556230	1115	1119	apoE	Gene	348
26556230	1129	1134	5XFAD	CellLine	CVCL:5U93
26556230	1135	1139	apoE	Gene	348
26556230	1145	1149	mice	Species	10090
26556230	1154	1159	5XFAD	CellLine	CVCL:5U93
26556230	1160	1164	apoE	Gene	348
26556230	1170	1174	mice	Species	10090
26556230	1190	1195	Abeta	Gene	11820
26556230	1208	1215	plaques	Disease	MESH:D003773
26556230	1244	1248	apoE	Gene	348
26556230	1270	1273	CAA	Disease	MESH:D016657
26556230	1317	1321	apoE	Gene	348
26556230	1327	1332	Abeta	Gene	11820
26556230	1336	1343	plaques	Disease	MESH:D003773
26556230	1351	1354	CAA	Disease	MESH:D016657
26556230	1409	1414	5XFAD	CellLine	CVCL:5U93
26556230	1415	1419	apoE	Gene	348
26556230	1425	1429	mice	Species	10090
26556230	1431	1438	plaques	Disease	MESH:D003773
26556230	1454	1460	murine	Species	10090
26556230	1461	1465	apoE	Gene	348
26556230	1547	1550	CAA	Disease	MESH:D016657
26556230	1566	1571	human	Species	9606
26556230	1572	1577	apoE4	Gene	348
26556230	1622	1625	CAA	Disease	MESH:D016657
26556230	1680	1685	mouse	Species	10090
26556230	1686	1690	apoE	Gene	348
26556230	1696	1701	Abeta	Gene	11820
26556230	1705	1712	plaques	Disease	MESH:D003773
26556230	1763	1768	mouse	Species	10090
26556230	1769	1773	apoE	Gene	348
26556230	1788	1793	Abeta	Gene	11820
26556230	1807	1811	apoE	Gene	348
26556230	1817	1821	mice	Species	10090
26556230	1836	1843	plaques	Disease	MESH:D003773
26556230	1852	1855	CAA	Disease	MESH:D016657
26556230	1902	1908	murine	Species	10090
26556230	1909	1913	apoE	Gene	348
26556230	1918	1923	human	Species	9606
26556230	1924	1929	apoE4	Gene	348
26556230	1986	1991	Abeta	Gene	11820
26556230	1992	1999	plaques	Disease	MESH:D003773
26556230	2007	2010	CAA	Disease	MESH:D016657
26556230	2055	2070	amyloid lesions	Disease	MESH:C000718787
26556230	Association	MESH:D003773	351
26556230	Association	MESH:D003773	348
26556230	Association	MESH:D000544	351
26556230	Association	11820	348
26556230	Association	MESH:D016657	348
26556230	Positive_Correlation	348	351
26556230	Association	MESH:D016657	351

